drugset / Trial / NCT04746131
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
Phase 1
Suspended
90 enrolled
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Worldwide Clinical Trials · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and efficacy of IMM0306-02 in patients with refractory or relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL).
Timeline
- Start
- 2021-01-15
- Primary completion
- 2024-04-11
- Completion
- 2024-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM0306 | Protein / enzyme biologic | 0.1 mg/kg | Intravenous |
| Subject | IMM0306 | Protein / enzyme biologic | 0.2 mg/kg | Intravenous |
| Subject | IMM0306 | Protein / enzyme biologic | 0.4 mg/kg | Intravenous |
| Subject | IMM0306 | Protein / enzyme biologic | 0.8 mg/kg | Intravenous |
| Subject | IMM0306 | Protein / enzyme biologic | 1.2 mg/kg | Intravenous |
| Subject | IMM0306 | Protein / enzyme biologic | 1.6 mg/kg | Intravenous |